The Quipt deal is good for shareholders, Leede says

Leede Financial analyst Douglas Loe changed his target on Quipt Home Medical (Quipt Home Medical Stock Quote, Chart, News, Analysts, Financials NASDAQ:QIPT) to “Tender” from “Buy” on Dec. 15 after the company agreed to be taken private in a cash transaction valuing the respiratory equipment provider at US$3.65 per share.

The offer comes from California-based Kingswood Capital Management and Alabama-based Forager Capital Management and implies an enterprise value of approximately US$257.6 million, based on fully diluted shares outstanding of 50.4 million. As of fiscal Q4 2025, Quipt reported US$12.9 million in cash and US$86.6 million in total debt.

Loe calculated the take-private valuation at 4.3× Quipt’s FQ4 2025 EBITDA run rate of roughly US$15.0 million, modestly above management’s own estimate of US$14.9 million. On a trailing-12-month basis, the transaction values Quipt at approximately 4.6× EBITDA, based on Loe’s estimate of US$56.1 million.

“By coincidence, our previous QIPT valuation was based on an essentially identical EBITDA multiple of 4.5×,” Loe said, noting that his prior target price reflected higher forward EBITDA assumptions rather than trailing results.

He said that the transaction multiple is broadly consistent with Quipt’s own acquisition history. Since becoming a public company, Quipt has completed 18 acquisitions of respiratory medical equipment distributors at an average EBITDA multiple of 4.7×, including recent deals such as GoodNight Medical and NorCal Respiratory at similar levels. The larger Great Elm Healthcare acquisition closed at a higher 6.2× EBITDA, while the September 2025 purchase of Harp Medical was completed at 4.2×.

“Quipt’s take-out value, while not aggressive by the standards of comparable public medical technology transactions, is consistent with the value Quipt itself has historically ascribed to acquired peers,” Loe said.

While the bid price remains below his prior US $4.50 target, Loe said the agreed consideration represents a meaningful premium to Quipt’s recent trading levels and likely caps near-term upside.

“Accordingly, we believe bid value represents a credible upper limit to where QIPT could trade in the medium term,” he said. “We are shifting our rating to Tender, with bid value representing an immediate return of approximately 35% from the prior closing price.”

-30-